SLAMF7

Synonyms

CS1, UNQ576/PRO1138, SLAMF7, Novel Ly9, SLAM Family Member 7, Membrane Protein FOAP-12, CD2 Subset 1, Protein 19A, CRACC, CD2-Like Receptor Activating Cytotoxic Cells, CD2-Like Receptor-Activating Cytotoxic Cells, 19A24 Protein, CD319, 19A, Novel LY9 (Lymphocyte Antigen 9) Like Protein, CD319 Antigen

Description

SLAM family member 7 is a protein that in humans is encoded by the SLAMF7 gene.SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. Isoform 1 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway. Positively regulates NK cell functions by a mechanism dependent on phosphorylated SH2D1B. Downstream signaling implicates PLCG1, PLCG2 and PI3K . In addition to heterotypic NK cells-target cells interactions also homotypic interactions between NK cells may contribute to activation. However, in the absence of SH2D1B, inhibits NK cell function. Acts also inhibitory in T-cells. May play a role in lymphocyte adhesion . In LPS-activated monocytes negatively regulates production of proinflammatory cytokines .Isoform 3 does not mediate any NK cell activation.

KO Status

RenMab: Immunization

RenLite: F0

Drug Information

Launched drug: 1
Drugs in clinical trials: 4
Latest Research Phase: Approved

Drug Name

Code

Phase

Company

Indications

Clinical Trials

Elotuzumab

PDL-063, HuLuc-63, BMS-901608

Approved

Abbvie Inc, Bristol-Myers Squibb Company

Smoldering Multiple Myeloma, Multiple Myeloma

CS1 Targeted CAR T-cells (Yake Biotechnology)

Phase 1 Clinical

Multiple Myeloma

BCMA-CS1 cCAR T cell therapy (iCell Gene Therapeutics)

Phase 1 Clinical

Icell Gene Therapeutics

Multiple Myeloma

UCART-CS1

UCART-38, UCART-CS1

Phase 1 Clinical

Cellectis

Multiple Myeloma

Anti-CD3/Anti-SLAMF7 Bispecific Antibody (University of Virginia)

Phase 1 Clinical

Multiple Myeloma

CD319 chimeric antigen T cell therapy (Wuhan Bio Raid Biotechnology)

Clinical

Wuhan Bio-Raid Biotechnology, Tongji Hospital

Hematologic Neoplasms

Azintuxizumab vedotin

ABBV-838

Discontinued

Abbvie Inc

Multiple Myeloma

References


Title

Authors

Source

The DNA sequence and biological annotation of human chromosome 1

Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., Bentley D.R.,

Nature 441:315-321(2006)

The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)

The MGC Project Team,

Genome Res. 14:2121-2127(2004)

Signal peptide prediction based on analysis of experimentally verified cleavage sites

Zhang Z., Henzel W.J.,

Protein Sci. 13:2819-2824(2004)

Molecular and functional characterization of a CS1 (CRACC) splice variant expressed in human NK cells that does not contain immunoreceptor tyrosine-based switch motifs

Lee J.K., Boles K.S., Mathew P.A.,

Eur. J. Immunol. 34:2791-2799(2004)

Mouse novel Ly9: a new member of the expanding CD150 (SLAM) family of leukocyte cell-surface receptors

Tovar V., Del Valle J., Zapater N., Martin M., Romero X., Pizcueta P., Bosch J., Terhorst C., Engel P.,

Immunogenetics 54:394-402(2002)

The cytotoxicity receptor CRACC (CS-1) recruits EAT-2 and activates the PI3K and phospholipase Cgamma signaling pathways in human NK cells

Tassi I., Colonna M.,

J. Immunol. 175:7996-8002(2005)

CS1 (SLAMF7) inhibits production of proinflammatory cytokines by activated monocytes

Kim J.R., Horton N.C., Mathew S.O., Mathew P.A.,

Inflamm. Res. 62:765-772(2013)

Systemic lupus erythematosus immune complexes increase the expression of SLAM family members CD319 (CRACC) and CD229 (LY-9) on plasmacytoid dendritic cells and CD319 on CD56(dim) NK cells

Hagberg N., Theorell J., Schlums H., Eloranta M.L., Bryceson Y.T., Roennblom L.,

J. Immunol. 191:2989-2998(2013)

Molecular cloning of CS1, a novel human natural killer cell receptor belonging to the CD2 subset of the immunoglobulin superfamily

Boles K.S., Mathew P.A.,

Immunogenetics 52:302-307(2001)

Activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family

Bouchon A., Cella M., Grierson H.L., Cohen J.I., Colonna M.,

J. Immunol. 167:5517-5521(2001)